Primary source: Pajama.ai via PR Newswire, November 16, 2026, 09:00 ET

Credo Acquired Affineon and Relaunched as Pajama.ai. The RCM Thread Is the Suspected Condition.

On November 16, 2026, Credo Health said it acquired Affineon Health and relaunched as Pajama.ai. Terms were not disclosed. Together they say they serve more than 200 clinical groups, 3,000 doctors, and 5 million patients. The product retrieves records, surfaces suspected conditions and care gaps, and automates inbox, lab, and refill work. If you run risk adjustment or a chart chase, the middle piece is the part that can become a code. The rest is pajama time. Keep that proportion.

Price not disclosed

Pajama says it automates 40% to 60% of inbox messages and cuts chart prep by three to five minutes per patient. Those are company claims in one sentence. The release offers a monthly subscription and does not state a price.

What the combination actually is

ElementWhat the release says
The dealCredo Health acquired Affineon Health and relaunched as Pajama.ai. Datelined Denver, November 16, 2026, 09:00 ET. Terms were not disclosed. It debuts at HLTH 2026, November 15–18, at The Venetian Expo. No booth number is in the release.
Credo's halfRecord retrieval that assembles a longitudinal chart. An insight engine for undiagnosed and suspected conditions, care gaps, medication issues, overdue screenings, and abnormal trends, “along with provider suggestions.”
Affineon's halfThe work after the visit: lab results, prescription renewals, and encounter workflows. Examples in the release: chart prep, emailing a patient about a normal result, and de-duplicating a renewal.
FootprintMore than 200 clinical groups, 3,000 doctors, and 5 million patients. The About line says more than 200 clinical groups, 3,000 providers, and more than 5 million patients.
Time claimDesigned to give each doctor back about 40 hours a month. The release says one in three family physicians still spend three or more hours a day on after-hours documentation, “according to 2026 federal data,” and it does not name the dataset.
PeopleCarm Huntress continues as CEO. The release says he previously founded Arrive Health, which brought real-time prescription drug pricing to 600,000 providers. Affineon CEO Evan Grossman becomes chief product officer. He spent nine years at athenahealth, helped build Zus Health with Jonathan Bush, and has worked on coding and billing at Innovaccer and CodeMetrix.

“Every doctor I know has a version of the same story: dinner, the kids go to bed, and then the laptop comes out,” said Huntress. “This acquisition helps us further our mission of lessening the administrative load providers are carrying. Credo helped providers walk into the exam room ready, while Affineon helped them stay caught up afterward. Together, we're giving providers a solution to the grueling hours of pajama time and giving them the time back that they deserve.”

“Affineon customers won't see anything change in the tools they rely on today. They'll just have more of their day back,” said Grossman. “The difference now is that we can bring Chart Prep to every practice already using our inbox automation, so providers are covered before and after the visit.”

Two named customers are in the release, and their numbers are theirs. Leslie Chiang, DO, of Peachtree Medical Center, a Chart Prep user: “I honestly don't want to see patients without it now. The insights provided often change my management on the spot, and I no longer have to wait on records that may never come.” Mia M. Painter, DNP, chief operating officer of San Marcos Family Medicine, an Affineon customer: “Since implementation, we've seen over a 50% reduction in our inbox volume across the board. This has been the best product implementation we've had in years, delivering real impact, efficiency, and improved patient care.” Painter's 50% is one practice's inbox. It is not the 40% to 60% company range, and it is not a collection rate.

Where this touches revenue cycle

Record retrieval is the same job as a chart chase. Payer and provider teams already buy that work when a risk-adjustment review or a medical-necessity file is short a note. Suspected conditions and care gaps are the findings that become an HCC if someone documents them and a coder submits them. The release says the engine surfaces those findings with provider suggestions. It does not say Pajama submits a claim, calculates a risk score, or guarantees RAF.

The inbox, the lab message, and the refill are clinical operations. The same morning, Commure bought an inbox company and was equally clear that the product lives in the message queue. Automating 40% to 60% of inbox messages, if a practice sees that, changes clinician time. It does not, by itself, change cost to collect. Grossman's coding and billing work at Innovaccer and CodeMetrix is a biography in the release. It is not a product announcement. Pajama does not say it is launching a coding module. The monthly subscription has no price in the release, and none is stated here.

RCAI analysis: one subscription, a narrow RCM exposure

This is RevCycleAI's read.

The acquisition puts chart retrieval and after-visit automation under one name. The revenue-cycle exposure is real and it is narrow. A suspected condition is how risk-adjustment documentation starts. A retrieved record is what a chart chase was for. Zus, which Grossman helped build, named risk adjustment as its revenue use case in the round RevCycleAI covered on November 10. That is context for the person, not a claim that Pajama is Zus.

A billing company should not read this as a new RCM platform. A risk-adjustment vendor should read it as another place those findings can show up before a coder opens the chart. The 40 hours a month, the three-to-five minutes, and the 40% to 60% are the company's design claims. The federal after-hours statistic is attributed only to “2026 federal data.”

The RCAI signal

Credo bought Affineon, price undisclosed, and relaunched as Pajama.ai across more than 200 clinical groups. The revenue-cycle link is suspected conditions, care gaps, and record retrieval. The 40% to 60% inbox figure is the company's claim. No subscription price was stated.

RCAI take

The open item is whether a suspected-condition suggestion gets documented, coded, submitted, and accepted, or whether it stops in the chart. The release does not say. It also does not say what the monthly subscription costs. Until one of those is printed, treat Pajama as chart prep plus inbox automation with a risk-adjustment adjacency, not as a billing system.

Sources: PR Newswire, “Credo Health Acquires Affineon, Launches Pajama.ai to End Doctors' Pajama Time,” November 16, 2026, 09:00 ET, Denver (page opened). Quotes from Carm Huntress, Evan Grossman, Leslie Chiang, and Mia M. Painter are verbatim from that release. The 200 groups, 3,000 doctors, 5 million patients, 40% to 60%, three to five minutes, about 40 hours a month, and the Arrive Health and Grossman biography are the release's. “2026 federal data” is unnamed in the release, and it is not named here. No subscription price was stated, and none is added.